Bioplatforms Australia and Phenomics Australia are proud to announce a new national initiative aimed at advancing knowledge of causality and treatment of mental disorders through large-scale omics data generation and high throughput phenomics. This initiative responds...
Bioplatforms Australia is collaborating with Therapeutic Innovation Australia (TIA), Phenomics Australia, and the Australian Nuclear Science and Technology Organisation (ANSTO) to address the medical products challenge outlined in the 2021 National Research...
The 2024 Nobel Prize in Chemistry was awarded to the team behind the transformative AI tool AlphaFold. In a major achievement for life sciences and biomedical research, the tool developed by DeepMind and released in 2020 enables rapid, accurate prediction of protein...
Bioplatforms Australia, enabled by NCRIS investment in research infrastructure, is committed to supporting the Australian life sciences community through a diverse access program, provision of targeted infrastructure requirements, and making integrated capability...
EMBL Australia has signed a Memorandum of Understanding (MOU) to join the NCRIS Health Group, strengthening Australian collaborative health research. The NCRIS Health Group, supported by the Australian Government’s National Collaborative Research Infrastructure...
Proteomics International Laboratories has released a groundbreaking study showing that its PromarkerD predictive test can effectively forecast renal decline in patients with type 1 diabetes. This exciting development, presented at the recent Australasian Diabetes...
